查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1834170

子宮內膜異位症治療市場（依治療類型、給藥途徑、最終用戶和分銷管道）—全球預測 2025-2032

Endometriosis Treatment Market by Treatment Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年子宮內膜異位症治療市場將成長至 54.8 億美元，複合年成長率為 7.58%。

主要市場統計數據
基準年2024年 30.5億美元
預計2025年 32.8億美元
預測年份：2032年 54.8億美元
複合年成長率（%） 7.58%

全面介紹塑造現代子宮內膜異位症治療生態系統的不斷發展的臨床方法、患者治療路徑和相關人員的優先事項

子宮內膜異位症是一種複雜的慢性婦科疾病，臨床需求多樣，治療週期長。近年來，該領域在診斷方法、患者期望、治療途徑和治療創新方面經歷了巨大變化。這些變化要求臨床醫生、付款方、製造商和護理提供者重新評估既定的常規治療方案，並適應及時診斷、個人化管理和整體患者支持至關重要的環境。

引言部分將讀者置於臨床實務與醫療保健系統動態的交會點。它整合了當代挑戰，包括延遲診斷、外科和內科管理的差異以及患者報告結果日益成長的重要性。它還強調了變革的促進因素，包括技術支援的診斷、新型藥理機制以及不斷變化的報銷壓力。透過從臨床、營運和商業性角度探討這個主題，它提出了對策略重點、相關人員權衡和實施障礙的預期，這些將在後續章節中進行探討。

總之，本介紹觀點旨在讓決策者對當前情況有一個簡明的了解，並強調為什麼結合臨床證據、供應連續性和以患者為中心的服務的整合策略對於改善長期結果和業務績效至關重要。

研究正在重塑子宮內膜異位症診斷途徑、護理模式和治療方法方案的快速臨床、技術和患者變化

在臨床進展、技術應用、支付方調整以及患者群體參與度提升的共同影響下，子宮內膜異位症的治療格局正在改變。臨床上，人們更重視早期發現和多學科干預，包括荷爾蒙管理、疼痛管理和微創手術（如有指徵）。同時，診斷輔助工具和數位化分流工具也開始縮短專科醫師就診時間，重塑病患就診的地點和時間。

在商業和營運方面，製造商和醫療保健提供者正在適應更差異化的治療組合和不斷變化的報銷環境。付款人和醫療保健系統正在優先考慮那些能夠顯著降低下游資源利用率並改善生活品質的干涉措施，從而推動對比較有效性和真實世界證據的審查。病患權益計劃和共用決策也在重新定義價值架構。患者在評估治療方法方案時，越來越重視症狀控制、生育能力保留以及對生活品質的影響。

綜上所述，這些變化迫使相關人員重新評估其產品開發策略、供應商教育和醫療准入舉措。成功的相關人員將把臨床證據的產生與切合實際的實施計劃相結合，這些計劃將考慮到不斷變化的診斷工作流程、多樣化的醫療環境以及對以患者為中心的治療結果日益成長的期望。

分析 2025 年美國關稅及其對供應鏈、籌資策略和患者獲得子宮內膜異位症治療的連鎖影響

關稅變化等政策槓桿可能會對藥品和器械供應鏈產生連鎖反應，子宮內膜異位症治療領域的相關人員應密切關注美國宣布的2025年關稅。這些關稅可能會影響子宮內膜異位症治療的原料藥、成品藥和手術耗材的採購。這些動態可能會增加依賴進口的供應鏈的管理複雜性，並鼓勵區域籌資策略。

營運團隊必須預測進口成本的增加將如何影響庫存策略、合約訂購和戰略儲備。採購團隊可以透過尋求多元化的供應商網路、協商長期合約或轉向大規模整合採購來應對波動。同時，製造商可以考慮本地生產或委託加工協議，以保持競爭性價格並最大限度地減少分銷摩擦。

從病人取得醫療服務的角度來看，關稅造成的中斷可能會重塑分銷管道和醫療機構的採購模式。實施臨時緩解措施，例如預購協議、一體化物流以及醫療機構網路之間的聯合採購，可以減輕短期影響。最終，積極評估供應鏈風險並調整籌資策略的相關人員將最有能力維持不間斷的醫療服務，並為病患保留治療選擇。

對子宮內膜異位症治療細分、ROA、治療前景和分銷管道的洞察將有助於確定子宮內膜異位症的臨床優先順序和服務提供

有意義的細分可以揭示臨床需求的分歧點以及可以應用操作槓桿的領域。依治療類型分類，子宮內膜異位症的治療涵蓋補充療法、荷爾蒙療法、疼痛管理和手術治療。荷爾蒙療法類別包括Aromatase抑制劑、促性腺激素釋放激素促效劑、促性腺激素釋放激素拮抗劑、口服避孕藥和黃體素，每種療法的療效、耐受性考慮和監測需求各不相同。疼痛管理策略包括使用非類固醇消炎劑)和鴉片類藥物，其中非類固醇消炎劑包括雙氯芬酸鈉、Ibuprofen和萘普生，鴉片類藥物包括可待因和氫可酮衍生物。

給藥途徑是另一個關鍵的區分因素，注射劑、口服劑和外用劑會影響依從性動態、就診頻率和供應物流。門診手術中心、醫院和專科診所必須分別考慮不同的手術能力、手術全期方案和影響治療順序的患者吞吐量。分銷管道完善了細分格局，因為醫院、線上和零售藥局的途徑會影響庫存管理、患者獲取時間表和治療諮詢機會。

整合這些層面，使相關人員能夠確定臨床教育、製劑設計和目標服務模式的介入點。能夠反映治療層級、給藥途徑、護理環境和分銷管道之間相互作用的策略決策，能夠更有效地滿足患者的不同需求，並簡化營運執行。

對子宮內膜異位症的臨床實踐、報銷框架和患者可近性進行區域分析，比較美洲、歐洲、中東和非洲地區以及亞太地區的情況

區域動態對子宮內膜異位症治療的提供和取得方式有著顯著的影響，各主要地區的實踐模式、法規環境和付款人政策有顯著差異。美洲地區通常由私人和公共付款人組成，加護治療中心和微創手術技術的採用率有所提高，而新藥選擇的可及性則因付款人政策和區域供應商關係而異。相較之下，歐洲、中東和非洲的國家醫療保健系統、監管時間表和報銷規則各不相同，導致新治療方法的採用率和對保留生育能力方法的重視程度各不相同。

亞太市場更加多元化，一些國家優先考慮快速採用創新診斷和護理途徑，以實現遠端醫療，而另一些國家則因供應鏈複雜性和報銷優先順序不同而面臨准入限制。此外，從醫院藥房網路到蓬勃發展的線上藥局服務的分銷管道的成熟度，將決定患者獲得急性治療和維持治療的可及性。

了解這些區域差異將有助於更好地分配資源、基於本地的證據產生以及製定具有商業性可行性的可近性策略。相關人員應根據當地監管要求和患者可近性實際情況，調整臨床支援、定價策略和供應模式，以最佳化療效並實現永續性。

子宮內膜異位症生態系統中的公司正在尋求各種策略佈局，這些策略將影響創新步伐和市場動態。現有的治療公司持續最佳化現有產品組合，選擇性地推進下一代荷爾蒙藥物以及針對疼痛和疾病進展的新機制。同時，規模較小的生物製藥和醫療設備公司則專注於利基適應症、輔助性治療和診斷技術，以縮短診斷時間並制定個人化治療方法方案。

在整個競爭格局中，授權合約、共同開發和商業合作等夥伴關係模式對於加速藥物取得和共用開發風險變得越來越重要。策略定位也延伸到真實世界證據產生和患者參與專案的能力，這些能力會影響付款人談判和臨床醫生的採用。投資於可證明的療效、精簡的製造地和彈性供應鏈的公司可以降低採用障礙，並與付款人和醫療保健提供者建立更牢固的關係。

最終，企業在研發優先事項、商業模式和生態系統夥伴關係關係方面的策略選擇將決定哪些公司能夠最有效地擴大其創新規模。那些將臨床證據與切合實際的部署策略和強大的患者支持系統相結合的公司，將最有可能在整個病人歷程旅程中產生永續的影響。

為領導者提供切實可行的建議，以加速診斷、改善治療途徑、增強供應彈性並改善子宮內膜異位症患者照護

透過採取優先且可操作的步驟，可以加速子宮內膜異位症治療的顯著改善。首先，投資臨床醫生和基層醫療的教育，以減少診斷延誤，並確保持續使用以指南為導向的出版途徑。其次，透過強調現實世界結果、生活品質指標和比較有效性，使證據產生策略與付款方優先事項保持一致，以支持將其納入醫療覆蓋範圍的討論和製定中。

第三，我們正在透過多元化供應商、探索區域製造方案以及實施策略性庫存實踐來增強供應鏈的韌性，以緩解關稅和物流中斷的影響。第四，我們正在設計以患者為中心的服務模式，整合藥物管理、疼痛控制策略、不孕症諮詢和心理社會支持，以滿足不孕症患者的多方面需求。第五，我們正在利用數位工具來促進遠端監控、依從性支持和分診，減少不必要的就診，並提高護理的連續性。

更精準的診斷和個人化治療能夠改善治療效果，從而支持付款方的價值，並為持續創新提供穩定的收入來源。領導者應優先考慮那些能帶來可衡量臨床效益，同時又能在現有醫療基礎設施內運作的干涉措施。

清晰說明研究框架、資料收集和檢驗過程以及用於深入了解子宮內膜異位症護理的分析方法。

本研究採用結構化、多源方法，確保研究結果的穩健性和可靠性。主要的定性輸入包括對臨床醫生、採購專業人員和患者權益倡導者的深入訪談，並輔以對同行評審的臨床研究、監管指南和實踐指南的二次資訊來源回顧。對這些輸入進行三角檢驗，以檢驗主題研究觀察，並識別臨床實踐和營運決策中的一致模式。

此分析方法結合了定性綜合分析、基於情境的供應鏈映射和相關人員影響分析。檢驗方案包括將訪談結果與公開的監管文件和程序標準進行交叉引用，並對醫療保健提供途徑的假設進行敏感性檢驗。研究盡可能強調證據來源與結論之間的透明度，以便使用者追蹤特定見解的形成過程。

調查方法優先考慮可重複性、清晰的假設和情境解讀，而非預測量化。資料來源、訪談架構和分析邏輯均清楚記錄，以支援臨床醫生、商業團隊和採購專業人員根據自身營運進行後續應用。

設定相關人員的優先事項，以改善子宮內膜異位症的診斷、護理服務和病患結果

總結總結匯集了臨床、營運和商業視角，旨在明確策略重點。診斷延遲、治療方案採用不均衡以及供應鏈漏洞是影響病患體驗和系統績效的持續性問題。為此，將臨床醫生教育、證據生成、彈性採購和以患者為中心的服務設計相結合的協作策略，是實現持久改進的最有希望的途徑。

相關人員應優先考慮能夠帶來切實臨床益處的干涉措施，同時解決影響可及性和依從性的後勤限制。例如，加強專家早期發表的途徑，使治療價值主張與付款方證據提案保持一致，以及投資於供應鏈冗餘以降低治療中斷的風險。重要的是，將患者的聲音納入研究和服務設計中，將透過展示生活品質的改善來提高相關性並加速應用。

摘要：取得進展需要多學科合作和切實可行的實施。將科學創新與實際操作現實和患者需求相結合，可以顯著改善子宮內膜異位症患者的醫療服務和預後。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 採用口服 GnRH 拮抗劑可促進個人化治療通訊協定，並減少副作用
  • 整合數位健康平台，用於子宮內膜異位症管理中的遠端監控和症狀追蹤
  • 針對減少子宮內膜病變的選擇性雌激素受體調節的臨床試驗正在增加
  • 擴大微創機器人輔助手術，改善病患復原和生育能力
  • 旨在減少慢性子宮內膜異位症發炎的生技藥品和免疫調節療法的成長
  • 增加對生物標記研究的投資，用於早期非侵入性診斷和監測疾病進展
  • 製藥和診斷公司合作開發荷爾蒙療法的伴隨診斷測試
  • 開發一種植入緩釋性藥物輸送系統，用於持續緩解子宮內膜異位症症狀

第6章 2025年美國關稅的累積影響

第7章 人工智慧的累積影響，2025年

第8章子宮內膜異位症治療市場（依治療類型）

  • 補充療法
  • 荷爾蒙療法
    • Aromatase抑制劑
    • GnRH促效劑
    • Gnrh拮抗劑
    • 口服避孕藥
    • 黃體素
  • 疼痛管理
    • NSAIDs
      • 雙氯芬酸鈉
      • Ibuprofen
      • 萘普生
    • 鴉片類藥物
      • 可待因
      • 氫可酮
  • 手術治療

9. 子宮內膜異位症治療市場（依給藥途徑）

  • 注射
  • 口服
  • 局部的

第 10 章子宮內膜異位症治療市場（依最終用戶分類）

  • 門診手術中心
  • 醫院
  • 專科診所

第11章子宮內膜異位症治療市場依通路分類

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第12章子宮內膜異位症治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章子宮內膜異位症治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 子宮內膜異位症治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc.
    • Bayer AG
    • Teva Pharmaceutical Industries Ltd
    • Ferring International Center SA
    • Mylan NV
    • Sandoz International GmbH
    • Lupin Limited
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd
    • Dr. Reddy's Laboratories Ltd.
Product Code: MRR-4348D129FA88

The Endometriosis Treatment Market is projected to grow by USD 5.48 billion at a CAGR of 7.58% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.05 billion
Estimated Year [2025] USD 3.28 billion
Forecast Year [2032] USD 5.48 billion
CAGR (%) 7.58%

Comprehensive introduction to evolving clinical approaches, patient pathways, and stakeholder priorities shaping modern endometriosis treatment ecosystems

Endometriosis is a complex, chronic gynecologic condition that drives diverse clinical needs and long trajectories of care. Over recent years, the field has experienced substantive changes in diagnostic approaches, patient expectations, care delivery pathways, and therapeutic innovation. These shifts require clinicians, payers, manufacturers, and care providers to reassess established routines and adapt to an environment where timely diagnosis, individualized management, and holistic patient support are paramount.

The introduction situates readers at the intersection of clinical practice and health system dynamics. It synthesizes contemporary challenges such as diagnostic delays, variability in surgical and medical management, and the increasing prominence of patient-reported outcomes. It also highlights the drivers of change, including technology-enabled diagnostics, new pharmacologic mechanisms, and evolving reimbursement pressures. By framing the topic across clinical, operational, and commercial dimensions, the narrative sets expectations for strategic priorities, stakeholder trade-offs, and implementation barriers that will be explored in subsequent sections.

In sum, this introductory perspective aims to equip decision-makers with a concise orientation to the current landscape, clarifying why integrated strategies that bridge clinical evidence, supply continuity, and patient-centered services are essential to improving long-term outcomes and operational performance.

Examination of rapid clinical, technological, and patient shifts reshaping diagnostic pathways, care delivery models and therapeutic choices in endometriosis care

The landscape of endometriosis treatment is shifting under the combined influence of clinical advances, technology diffusion, payer recalibration, and more engaged patient communities. Clinically, there is a clearer emphasis on earlier recognition and on integrating multimodal interventions that combine hormonal management, pain control, and minimally invasive surgery when indicated. Concurrently, diagnostic adjuncts and digital triage tools are starting to reduce time to specialist referral, reshaping where and when patients enter care pathways.

On the commercial and operational side, manufacturers and providers are adapting to more differentiated therapeutic portfolios and variable reimbursement environments. Payers and health systems are prioritizing interventions that demonstrably reduce downstream resource utilization and improve quality of life, prompting deeper scrutiny of comparative effectiveness and real-world evidence. Patient advocacy and shared decision-making are also redefining value frameworks: patients increasingly weigh symptom control, fertility preservation, and quality-of-life impacts when evaluating therapy options.

Taken together, these transformative shifts compel stakeholders to reevaluate product development strategies, provider education, and access initiatives. Successful actors will align clinical evidence generation with pragmatic implementation plans that account for evolving diagnostic workflows, heterogeneous care settings, and rising expectations for patient-centered outcomes.

Analysis of US tariff measures in 2025 and their cascading effects on supply chains, procurement strategies, and patient access to endometriosis therapies

Policy levers such as tariff changes can ripple through pharmaceutical and device supply chains, and the announced United States tariff measures for 2025 warrant careful attention from stakeholders involved in endometriosis care. Tariff-driven cost pressures may alter supplier selection and procurement practices, with implications for sourcing of active pharmaceutical ingredients, finished medicines, and surgical consumables used in endometriosis management. These dynamics can raise the administrative complexity of import-dependent supply lines and incentivize regional sourcing strategies.

Operational teams must anticipate how increased import costs could influence inventory policy, contracting cadence, and strategic stockpiles. Procurement groups may respond by seeking diversified supplier networks, negotiating longer-term agreements, or shifting toward larger consolidated purchases to mitigate volatility. Providers and specialty clinics should evaluate formulary implications as product economics change; meanwhile, manufacturers may consider localized manufacturing or tolling arrangements to preserve competitive pricing and minimize distribution friction.

From a patient access perspective, tariff-induced disruptions can reshape availability patterns across distribution channels and care settings. Transitional mitigation measures, such as advance purchase agreements, consolidated logistics, and collaborative sourcing among provider networks, can attenuate short-term impacts. Ultimately, stakeholders that proactively assess supply chain exposures and adapt procurement strategies will be better positioned to sustain uninterrupted care and preserve therapeutic choice for patients.

Insights into treatment segments, ROA, care settings, and distribution pathways that inform clinical priorities and service delivery for endometriosis

Meaningful segmentation illuminates where clinical needs diverge and where operational levers can be applied. When viewed through treatment type, endometriosis management spans Complementary Therapies, Hormonal Therapies, Pain Management, and Surgical Treatment. Hormonal Therapies encompass classes such as Aromatase Inhibitors, GnRH Agonists, GnRH Antagonists, Oral Contraceptives, and Progestins, each carrying distinct efficacy profiles, tolerability considerations, and monitoring needs. Pain Management strategies include the use of NSAIDs and Opioids, and the NSAID category itself is commonly represented by agents such as Diclofenac, Ibuprofen, and Naproxen, while opioid options frequently involve codeine and morphine derivatives; these choices implicate different safety monitoring and prescribing frameworks.

Route of administration is another critical differentiator, with injectable, oral, and topical modalities shaping adherence dynamics, clinic visit frequency, and supply logistics. End user settings also matter materially: ambulatory surgical centers, hospitals, and specialty clinics each offer different procedural capabilities, perioperative protocols, and patient throughput considerations that affect treatment sequencing. Distribution channels complete the segmentation picture, as hospital pharmacy, online pharmacy, and retail pharmacy pathways influence inventory management, patient access timelines, and opportunities for therapeutic counseling.

By synthesizing these layers, stakeholders can identify intervention points for clinical education, formulary design, and targeted service models. Strategic decisions that reflect the interplay between therapeutic class, administration route, care setting, and distribution pathway will more effectively meet heterogeneous patient needs and streamline operational execution.

Regional analysis of clinical practice, reimbursement frameworks, and patient access that contrasts the Americas, EMEA, and Asia-Pacific landscapes in endometriosis

Regional dynamics exert a strong influence on how endometriosis care is delivered and accessed, with meaningful variation in practice patterns, regulatory environments, and payer policies across major geographies. The Americas tend to reflect a mix of private and public payer arrangements, with centralized centers of excellence and growing adoption of minimally invasive surgical techniques, while access to new pharmacologic options varies according to payer policy and regional supplier relationships. By contrast, Europe, the Middle East & Africa display a heterogeneous mosaic of national healthcare systems, regulatory timelines, and reimbursement rules, leading to varied adoption rates for novel therapies and differing emphases on fertility-preserving approaches.

Asia-Pacific markets present additional diversity: some jurisdictions prioritize rapid adoption of innovative diagnostics and telehealth-enabled care pathways, while others face access constraints driven by supply chain complexity and differing reimbursement priorities. Across regions, the balance between hospital-centric procedures and ambulatory care alternatives affects where patients receive surgery and follow-up, and distribution channel maturity-from hospital pharmacy networks to rapidly growing online pharmacy services-shapes patient access to both acute and maintenance therapies.

Understanding these regional contrasts enables more precise allocation of resources, localized evidence generation, and commercially realistic access strategies. Stakeholders should tailor clinical support, pricing strategies, and supply models to regional regulatory imperatives and patient access realities to optimize outcomes and sustainability.

Companies operating in the endometriosis ecosystem are pursuing a range of strategic plays that impact innovation velocity and market dynamics. Established therapeutics manufacturers continue to optimize existing portfolios while selectively advancing next-generation hormonal agents and novel mechanisms that target pain and lesion progression. At the same time, smaller biopharma and device innovators focus on niche indications, adjunctive therapies, and technology-enabled diagnostics designed to improve time to diagnosis and personalize treatment selection.

Across the competitive landscape, partnership models-such as licensing agreements, co-development collaborations, and distribution alliances-are increasingly important for accelerating access and sharing developmental risk. Strategic positioning also extends to capabilities in real-world evidence generation and patient engagement programs, which influence payer negotiations and clinician adoption. Firms that invest in demonstrable outcomes, streamlined manufacturing footprints, and resilient supply chains will reduce barriers to adoption and build stronger payer and provider relationships.

Ultimately, corporate strategic choices around R&D prioritization, commercial models, and ecosystem partnerships will determine who can scale innovations most effectively. Companies that integrate clinical evidence with pragmatic deployment strategies and robust patient support systems will emerge best positioned to deliver sustainable impact across the patient journey.

Actionable recommendations for leaders to expedite diagnosis, refine therapeutic pathways, strengthen supply resilience, and elevate patient care in endometriosis

Actionable, prioritized steps can help organizations accelerate meaningful improvements in endometriosis care. First, invest in clinician and primary care education to reduce diagnostic delays and ensure consistent use of guideline-based referral pathways; earlier identification streamlines care and expands therapeutic options. Second, align evidence-generation strategies with payer priorities by emphasizing real-world outcomes, quality-of-life metrics, and comparative effectiveness to support coverage discussions and formulary inclusion.

Third, strengthen supply chain resilience by diversifying suppliers, exploring regional manufacturing options, and implementing strategic inventory practices to mitigate tariff or logistics disruptions. Fourth, design patient-centered service models that integrate pharmacologic management, pain control strategies, fertility counseling, and psychosocial support to address the multifaceted needs of individuals living with the condition. Fifth, leverage digital tools to facilitate remote monitoring, adherence support, and triage, thereby reducing unnecessary visits and enhancing continuity of care.

When implemented cohesively, these recommendations create a reinforcing cycle: better diagnosis and tailored therapies improve outcomes, which in turn support payer value arguments and stabilize revenue streams necessary for continued innovation. Leaders should prioritize interventions that deliver measurable clinical benefit while remaining operationally feasible within existing care infrastructures.

Clear description of research framework, data collection and validation processes, and analytical methods applied to derive insights on endometriosis care

This research applied a structured, multi-source approach to ensure the robustness and credibility of findings. Primary qualitative inputs included in-depth interviews with clinicians, procurement specialists, and patient advocates, complemented by secondary literature reviews of peer-reviewed clinical studies, regulatory guidances, and practice guidelines. Triangulation across these inputs was used to validate thematic findings and identify consistent patterns across clinical practice and operational decision-making.

Analytical methods combined qualitative synthesis with scenario-based supply chain mapping and stakeholder impact analysis. Validation protocols included cross-checking interview insights with publicly available regulatory documents and procedural standards, and applying sensitivity checks to assumptions about care delivery pathways. Wherever possible, the research emphasized transparent linkage between evidence sources and derived conclusions, enabling users to trace how specific insights were developed.

The methodology prioritized reproducibility, clarity of assumptions, and contextual interpretation rather than predictive quantification. Clear documentation of data sources, interview frameworks, and analytic logic supports downstream application by clinicians, commercial teams, and procurement professionals seeking to adapt the insights to their own operational contexts.

Concluding synthesis of key findings and implications setting priorities for stakeholders to improve diagnosis, care delivery, and patient outcomes in endometriosis

The concluding synthesis brings together clinical, operational, and commercial perspectives to clarify strategic priorities. Delays in diagnosis, heterogeneous adoption of therapeutic options, and supply chain vulnerabilities emerge as persistent themes that shape patient experience and system performance. In response, coordinated strategies that combine clinician education, evidence generation, resilient procurement, and patient-focused service design provide the most promising avenue for durable improvement.

Stakeholders should prioritize interventions that deliver tangible clinical benefit while also addressing logistical constraints that influence access and adherence. Examples include bolstering pathways for early specialist referral, aligning therapeutic value propositions with payer evidence needs, and investing in supply chain redundancies that reduce the risk of therapeutic interruptions. Importantly, integrating patient voice into research and service design amplifies relevance and can accelerate uptake through demonstrable improvements in quality of life.

In summary, the path forward requires multidisciplinary collaboration and pragmatic implementation. By aligning scientific innovation with operational realism and patient priorities, the sector can advance meaningful improvements in care delivery and outcomes for people affected by endometriosis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of oral GnRH antagonists driving personalized treatment protocols with reduced side effects
  • 5.2. Integration of digital health platforms for remote monitoring and symptom tracking in endometriosis management
  • 5.3. Increasing clinical trials exploring selective estrogen receptor modulators for targeted endometrial lesion reduction
  • 5.4. Expansion of minimally invasive robotic-assisted surgeries to improve patient recovery and fertility outcomes
  • 5.5. Growth of biologics and immunomodulatory therapies aimed at inflammation control in chronic endometriosis cases
  • 5.6. Rising investment in biomarker research for early noninvasive diagnosis and disease progression monitoring
  • 5.7. Collaborations between pharmaceutical and diagnostic companies to develop companion diagnostic tests for hormone therapies
  • 5.8. Development of implantable extended-release drug delivery systems for sustained endometriosis symptom relief

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endometriosis Treatment Market, by Treatment Type

  • 8.1. Complementary Therapies
  • 8.2. Hormonal Therapies
    • 8.2.1. Aromatase Inhibitors
    • 8.2.2. Gnrh Agonists
    • 8.2.3. Gnrh Antagonists
    • 8.2.4. Oral Contraceptives
    • 8.2.5. Progestins
  • 8.3. Pain Management
    • 8.3.1. Nsaids
      • 8.3.1.1. Diclofenac
      • 8.3.1.2. Ibuprofen
      • 8.3.1.3. Naproxen
    • 8.3.2. Opioids
      • 8.3.2.1. Codeine
      • 8.3.2.2. Morphine
  • 8.4. Surgical Treatment

9. Endometriosis Treatment Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical

10. Endometriosis Treatment Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Endometriosis Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Endometriosis Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Endometriosis Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Endometriosis Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AbbVie Inc.
    • 15.3.2. Bayer AG
    • 15.3.3. Teva Pharmaceutical Industries Ltd
    • 15.3.4. Ferring International Center S.A.
    • 15.3.5. Mylan N.V.
    • 15.3.6. Sandoz International GmbH
    • 15.3.7. Lupin Limited
    • 15.3.8. Pfizer Inc.
    • 15.3.9. Sun Pharmaceutical Industries Ltd
    • 15.3.10. Dr. Reddy's Laboratories Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ENDOMETRIOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ENDOMETRIOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ENDOMETRIOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY CODEINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY MORPHINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER